Catalent Pharma Solutions, a services and solutions provider, and BASF, a leading chemical company, have formed an open alliance to provide solutions to overcome bioavailability challenges of new molecular entities with solubility or permeability challenges. 

The companies will combine their expertise to provide pharmaceutical customers with a unique range of seamless solutions to address pipeline challenges with a large majority of BCS Class II and IV poorly bioavailable compounds.  Ranging from feasibility studies across multiple technologies, solid state chemistry, consulting and training, expert formulation services, excipients and optimal dose form development, to scale-up and supply, BASF and Catalent aim to provide a full solution to an important pipeline challenge in the industry—getting better treatments to market faster. 

"With our broadest portfolio of solubilizers and excipients for hot-melt extrusion, coupled with Catalent’s strengths in development, formulation and manufacturing, we are in a unique position to solve the solubility challenge,” said Ralf Fink, vice president of global marketing, BASF pharma ingredients and services business unit. “With this open alliance, we help our customers in the development and commercialization of drugs with poor bioavailability.”